Interactive Network Platform Improves Compliance and Efficacy of Subcutaneous Immunotherapy for Patients with Allergic Rhinitis
Authors Shen Z, Tan G, Zhong Z, Ding S, Wang F
Received 23 October 2019
Accepted for publication 9 December 2019
Published 13 December 2019 Volume 2019:13 Pages 2101—2110
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Naifeng Liu
Zhiying Shen,1 Guolin Tan,2 Zhuqing Zhong,1 Siqing Ding,1 Fang Wang2
1Nursing Department, Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China; 2Department of Otolaryngology Head Neck Surgery, Third Xiangya Hospital, Central South University, Changsha, People’s Republic of China
Correspondence: Fang Wang
Department of Otolaryngology Head Neck Surgery, Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Changsha 410013, People’s Republic of China
Tel/Fax +86 731-88618624
Background: Allergic rhinitis (AR) is a common chronic inflammatory disease of nasal mucosa worldwide, and its symptoms seriously affect the lives of patients. Subcutaneous immunotherapy (SCIT) is an effective treatment for AR, but it is also associated with low patient compliance and difficulties in fully achieving therapeutic effects.
Objective: In this prospective randomized controlled study, we verified the effects of an interactive network platform named “U breath” in improving patient compliance and the efficacy of SCIT in patients with AR.
Methods: A total of 148 patients who received SCIT were recruited as participants and randomly assigned to either the standardized management (SM) or the interactive network platform management (INP) group. The SM group experienced the standard management SCIT process. The INP group experienced a new management approach based on an interactive network platform called “U breath”. The compliance rate, combined symptom and medication score (CSMS), visual analogue scale score and the rhinoconjunctivitis quality of life questionnaire (RQLQ) results were evaluated at baseline and 1-year postintervention for the two groups.
Results: Within the first year of treatment, the INP group had a higher compliance rate than did the SM group, with a statistically significant difference (P<0.05). The INP group showed better clinical improvement than the SM group did in terms of the VAS score, and the RQLQ score except the sleep problems (P< 0.05).
Conclusion: This study confirmed that the application of an interactive network platform is of great significance for improving patient compliance and the treatment effects of SCIT in patients with AR.
Keywords: allergic rhinitis, subcutaneous immunotherapy, compliance, quality of life, network, management
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]